Genetesis was founded in Mason in 2013 and employs 10 people. It will use the funding to scale its engineering, launch additional clinical studies and seek regulatory clearance from the FDA.
“The Genetesis technology opens broad new commercial markets for what has, for decades, been primarily a research tool. For millions dealing with the risks and anxiety of arrhythmias, atrial fibrillation and other cardiac diseases, this is a game changer,” Cuban said in a statement.
Genetesis co-founder and CEO Peeyush Shrivastava presented findings Nov. 15 at the American Heart Association Scientific Sessions. The data was collected in collaboration with Mayo Clinic, he said in a statement.
“These results demonstrate promising improvements for the noninvasive detection of ischemia in patients with high-risk chest pain, as compared to tools available in the emergency room today,” Shrivastava said.